FDA Adds To 510(k) Exemptions List, Responding To Lost, Now Found, Public Comments
This article was originally published in The Gray Sheet
Executive Summary
FDA updated its guidance on exempting certain unclassified and class II/class I devices from 510(k) requirements by adding eight additional products to the earlier list of 120 exempted. The codes were recommended in public comments that FDA neglected to review prior to publishing its original July 1 guidance.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.